Recommendations for Premarket Notification Submissions for Nucleic Acid-Based Human Leukocyte Antigen (HLA) Test Kits Used for Transfusion and Transplantation

Recommendation
7/8 October 2025
- From Bench to Bedside -
In November, the FDA published a "Draft Guidance for Industry: Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen (HLA) Test Kits Used for Transfusion and Transplantation".
In its introduction the authority states:
"This guidance provides recommendations to submitters and FDA reviewers in preparing and reviewing premarket 510(k) submission for human leukocyte antigen (HLA) in vitro diagnostic (IVD) device test kits. This guidance applies specifically to nucleic acid-based HLA test kits used for the matching of donors and recipients in transfusion and transplantation, whether testing is for a single locus or for multiple loci simultaneously, for which the premarket submission to FDA will be a 510(k). Although this guidance applies specifically to 510(k) submissions for HLA test kits, some of the recommendations below may also be applicable to human neutrophil antigen (HNA) and human platelet antigen (HPA) test kits. The document provides detailed information on the types of studies FDA recommends for validation of HLA test kits submitted as 510(k)s and used for the matching of donors and recipients in transfusion and transplantation."
For more information please see the complete Draft Guidance.
Related GMP News
03.09.2025Standardisation of Monoclonal Antibodies (mAbs) by the EPC
03.09.2025 USP publishes revision of chapter <111> Design and Analysis of Biological Assays
20.08.2025USP Chapter <1049.1> Stability Studies for Biotechnological and Biological Products
22.05.2025FDA Initiates Transition to Non-Animal Testing Methods for Monoclonal Antibodies
22.05.2025FDA Warning Letter: Unauthorised Distribution of Fecal Microbiota Transplant Products